HZHuajun Zhang

Huajun Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huajun Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Hanyang Su

    Department of Respiratory Medicine & Teaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Jie Wang

    Department of Physiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China

    1 shared publication
  • Xiangqian Zhang

    Department of Oncology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Xiaojin Liu

    Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Xinyu Cao

    Department of Physiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China

    1 shared publication

Latest Publications

  • Open Access

    ITGAV as a promising diagnostic, immunological, and prognostic biomarker in pan-cancer

    by Hanyang Su, Jie Wang, Xinyu Cao, Xiangqian Zhang, Huajun Zhang, Xiaojin Liu

    Integrin αV (ITGAV) plays a key role in cell adhesion, migration, and immune regulation, and is implicated in tumor progression. However, its comprehensive expression profile and functional relevance across different cancers remain poorly understood. We conducted an integrative pan-cancer analysis of ITGAV using data from TCGA, GTEx, CCLE, and other public databases. Expression, diagnostic value (via ROC analysis), and prognostic significance (via Cox and Kaplan–Meier analyses of OS, DSS, PFS, and DFS) were assessed. We further explored ITGAV’s correlation with immune cell infiltration and immune-related genes, its predictive role in immunotherapy response based on immunophenoscore (IPS), and its drug-binding potential through molecular docking. (1) ITGAV was significantly overexpressed in multiple cancer types including LIHC, COAD, and STAD. (2) ROC analysis confirmed its strong diagnostic value, particularly in HNSC, UCEC, and ESCA. (3) High ITGAV expression was associated with poorer survival outcomes in most cancers, while a protective role was observed in KIRC. (4) ITGAV expression was positively correlated with immune cell infiltration and co-expressed with immune-activating and immunosuppressive genes. (5) The expression level of ITGAV correlates with the IPS score, suggesting its predictive value for the benefit of immunotherapy. (6) Molecular docking identified strong binding affinities between ITGAV and six candidate compounds, including gemcitabine and pioglitazone. Our findings demonstrate that ITGAV is a promising biomarker for diagnosis, prognosis, and immunotherapy prediction across cancers. Its immunological associations and druggability highlight its potential as a candidate therapeutic target.